1402581-75-2

Upstream product

• 1254713-79-5 (1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methanamine 
• 1402586-16-6 N-[4-[[(tert-butoxycarbonyl-sulfamoyl)amino]-methyl]-phenyl]-carbamic acid phenyl ester 
• 116853-75-9 C₈H₆ClF₃N₂ 
• 1254713-76-2 hydrazonoyl chloride 
• 619-73-8 4-nitrobenzyl chloride 
• 39628-94-9 4-nitrobenzyl methanesulfonate 
• 62133-07-7 2-(4-nitrobenzyl)-1H-isoindole-1,3(2H)-dione 
• 7409-30-5 p-nitrobenzylamine 
• 99-99-0 1-methyl-4-nitrobenzene 
• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 1402586-14-4 tert-butyl N-(4-nitrobenzyl)sulfamoylcarbamate 
• 1402586-15-5 tert-butyl N-(4-aminobenzyl)sulfamoyl-carbamate 
• 1402586-17-7 C₂₄H₂₆ClF₃N₆O₅S 
• 1254713-77-3 1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carbonitrile 

Relevant academic research and scientific papers

SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH AN N-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives of formula (R) bearing a phenyl moiety substituted with an N-containing group as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.